Animal models for acute radiation syndrome drug discovery

Expert Opinion on Drug Discovery
Vijay K SinghThomas J Macvittie

Abstract

Although significant scientific advances have been made over the past six decades in developing safe, nontoxic and effective radiation/medical countermeasures (MCMs) for acute radiation syndrome (ARS), no drug has been approved by the US FDA. The availability of adequate animal models is a prime requisite under the criteria established by the FDA 'animal rule' for the development of novel MCMs for ARS and the discovery of biomarkers for radiation exposure. This article reviews the developments of MCMs to combat ARS, with particular reference to the various animal models (rodents: mouse and rat; canine: beagle; minipigs and nonhuman primates [NHPs]) utilized for the in-depth evaluation. The objective, pathways and challenges of the FDA Animal Efficacy Rule are also discussed. There are a number of well-defined animal models, the mouse, canine and NHP, that are being used for the development of MCMs. Additional animal models, such as the minipig, are under development to further assist in the identification, efficacy testing and approval of MCMs under the FDA Animal Efficacy Rule.

References

Oct 1, 1976·International Journal of Radiation Biology and Related Studies in Physics, Chemistry, and Medicine·H CroizatM Tubiana
Apr 1, 1990·International Journal of Radiation Biology·T J MacVittieL M Souza
Apr 1, 1990·International Journal of Radiation Biology·J W Hopewell
Mar 1, 1989·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·K BaltschukatW Nothdurft
Aug 1, 1985·Gastroenterology·E Danquechin DorvalA Dubois
Dec 1, 1987·Digestive Diseases and Sciences·R W SummersF A Mitros
Oct 1, 1984·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·C W ScarantinoL S Constine
Dec 1, 1995·Plastic and Reconstructive Surgery·C J GabkaT K Hunt
Jan 1, 1995·Digestive Diseases and Sciences·J L HerreraA Dubois
Apr 1, 1997·Health Physics·R E GoansR C Ricks
Jan 19, 1999·The American Journal of the Medical Sciences·F L MakrauerJ Shumaker
May 18, 2000·International Journal of Radiation Biology·J W HopewellH F Moustafa
Oct 19, 2000·Journal of Basic and Clinical Physiology and Pharmacology·M KrimskyS Yedgar
Oct 21, 2000·Seminars in Radiation Oncology·Z VujaskovicM S Anscher
Jul 12, 2001·Seminars in Radiation Oncology·E L Travis
Aug 3, 2001·International Journal of Radiation Oncology, Biology, Physics·J W DenhamL J Peters
Aug 21, 2001·International Review of Cytology·K E Carr
Mar 14, 2002·The American Journal of Pathology·Kathleen C FlandersAnita B Roberts
Jun 14, 2002·Experimental Hematology·Nicholas Dainiak
Aug 7, 2003·Seminars in Radiation Oncology·Lawrence B MarksMitchell S Anscher
Jan 22, 2004·The Journal of Immunology : Official Journal of the American Association of Immunologists·Julia KaufmanRichard P Phipps
Jun 16, 2004·Annals of Internal Medicine·Jamie K WaselenkoUNKNOWN Strategic National Stockpile Radiation Working Group
Dec 14, 2004·International Journal of Radiation Oncology, Biology, Physics·Liguang ChenZeljko Vujaskovic
Jun 22, 2005·Radiation Research·Alison Deckhut AugustineSara Rockwell
Oct 12, 2005·Health Physics·Thomas M Seed
Nov 16, 2005·Journal of Radiological Protection : Official Journal of the Society for Radiological Protection·F C A Da SilvaV R Crispim

❮ Previous
Next ❯

Citations

Jul 3, 2015·Expert Opinion on Therapeutic Patents·Vijay K Singh, Harvey B Pollard
Nov 17, 2015·Expert Review of Molecular Diagnostics·Vijay K SinghHarvey B Pollard
Mar 20, 2016·Tissue Engineering. Part C, Methods·Yu-Suke TorisawaDonald Ingber
May 7, 2016·International Journal of Molecular Sciences·Vijay K Singh, Martin Hauer-Jensen
Jul 7, 2016·Laboratory animal research·Seung-Hyun RyuYang-Kyu Choi
Aug 23, 2016·Expert Opinion on Drug Discovery·Vijay K SinghMartin Hauer-Jensen
Apr 27, 2017·Expert Opinion on Drug Discovery·Vijay K Singh, Ayodele O Olabisi
Jan 16, 2018·Stem Cells International·Vivian Fonseca GonzagaIrina Kerkis
Apr 26, 2018·Journal of Radiological Protection : Official Journal of the Society for Radiological Protection·Jonathan S Eakins, Elizabeth A Ainsbury
Apr 26, 2018·Journal of Radiological Protection : Official Journal of the Society for Radiological Protection·Jonathan S Eakins, Elizabeth A Ainsbury
Dec 14, 2018·Maxillofacial Plastic and Reconstructive Surgery·Hong-Moon JungTae-Geon Kwon
Jul 17, 2020·Science Translational Medicine·Marshleen YadavNaduparambil K Jacob
Nov 6, 2018·International Journal of Molecular Sciences·Amrita K CheemaVijay K Singh
Jan 10, 2021·Scientific Reports·M H YashavarddhanSandeep Kumar Shukla
Oct 17, 2020·Drug Discovery Today·Vijay K Singh, Thomas M Seed
Feb 14, 2021·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Harshani WijerathneMohammad F Kiani
May 15, 2021·Frontiers in Pharmacology·Meetha MedhoraAniko Szabo
Apr 14, 2021·International Journal of Radiation Oncology, Biology, Physics·Priyanka ThakurJ Mark Cline
Jun 22, 2021·Radiation Research·J SaundersJ Palis
Aug 27, 2021·Metabolites·Se-Ran JunMartin Hauer-Jensen
Aug 31, 2021·Expert Opinion on Drug Discovery·Vijay K Singh, Thomas M Seed

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.